The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseKenneth A. Freedberg, Sue J. Goldie, April D. Kimmel et al.|New England Journal of Medicine|2001Cited by 519
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsMark Nelson, Miklos Salgo, Keikawus Arastéh et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005Cited by 151
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Brian P. Kearney, Richard Elion et al.|AIDS|2011Cited by 109
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infectionRichard Elion, David R. Warren, Calvin Cohen et al.|AIDS|2011Cited by 92